Therapeutics News and Research

RSS

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.

8 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.

6 Apr 2013

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.

5 Apr 2013

UNC study shows promise for uncovering true mechanisms of human stem cell biology

For the first time, researchers at the University of North Carolina at Chapel Hill have isolated adult stem cells from human intestinal tissue.

5 Apr 2013

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers.

4 Apr 2013

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.

4 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Sanford-Burnham Medical Research Institute at Lake Nona announced the selection of the first five research organizations that will participate in the Florida Translational Research Program to advance drug discovery in the state.

3 Apr 2013

Texas Tech Professor receives NIH grant to research on leishmaniasis

A Texas Tech University biology professor received a five-year, $1.6 million grant from the National Institutes of Health to study the biochemistry of a microscopic parasite responsible for the tropical disease leishmaniasis in the hope of finding a cure.

2 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

Study links mutated histone protein to rare brain stem cancer in children

Most cancer treatments are blunt. In an attempt to eradicate tumors, oncologists often turn to radiation or chemotherapy, which can damage healthy tissue along with the cancerous growths.

2 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Therapeutics News and Research

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

GenSight Biologics announces closing of €32 million Series A financing

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

UNC study shows promise for uncovering true mechanisms of human stem cell biology

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

Polymer scaffolds can advance the development of cancer therapeutics

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Texas Tech Professor receives NIH grant to research on leishmaniasis

Revance Therapeutics raises $33M in Series E financing

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Adenosine Therapeutics to explore strategic options for Stedivaze

Study links mutated histone protein to rare brain stem cancer in children

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News